2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
105
Carcinoma, Hepatocellular
34
Neoplasm Metastasis
19
Neoplasms
17
Gastrointestinal Stromal Tumors
17
Colonic Neoplasms
14
Rectal Neoplasms
12
Liver Neoplasms
8
Glioblastoma
7
Sarcoma
6
Stomach Neoplasms
5
Sarcoma, Ewing
5
Ovarian Neoplasms
5
Osteosarcoma
5
Melanoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Rhabdomyosarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Leukemia, Myeloid, Acute
3
Colorectal Cancer Metastatic
3
Carcinoma, Transitional Cell
3
Carcinoma
3
Advanced Colorectal Cancer
3
Thyroid Neoplasms
2
Interventions
Fluorouracil
4
lenvatinib
3
Surgical Procedures, Operative
3
Oxaliplatin
3
Leucovorin
3
Drug Therapy
3
Gemcitabine
2
Folfox protocol
2
Floxuridine
2
regorafenib
1
gemcitabine-oxaliplatin regimen
1
durvalumab
1
donafenib
1
apatinib
1
Radiotherapy
1
Irinotecan
1
Hepatectomy
1
Dexamethasone
1
Cryosurgery
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cirrhosis, Familial, with Pulmonary Hypertension
×
regorafenib
×
Clear all
NCT06946849
2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
76 enrolled